drugset / Trial / NCT03396497
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the combination for biologic and clinical activity in NSCLC.
Timeline
- Start
- 2018-08-03
- Primary completion
- 2019-10-20
- Completion
- 2019-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CINTIRORGON | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |